Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.59 |
| ▸ | PDGFRA | P16234 | 5/20 | 0.57 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | KDR | P35968 | 3/20 | 0.56 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200371 | 0.87 | AXL (0.55) | METPDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL4203611 | 0.87 | KDR (0.53) | METPDGFRAPDGFRBKDR | |
| SCHEMBL4211584 | 0.86 | MET (0.55) | METPDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL4508946 | 0.86 | PDGFRB (0.61) | METPDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL4501657 | 0.86 | KDR (0.64) | METPDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL2172904 | 0.84 | PDGFRA (0.64) | METPDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL4209562 | 0.83 | SRC (0.53) | METPDGFRAPDGFRBKDRKIT | |
| SCHEMBL2176217 | 0.82 | PDGFRB (0.67) | METPDGFRAPDGFRBKDRFGFR2 | |
| SCHEMBL4498768 | 0.82 | PDGFRB (0.65) | METPDGFRAPDGFRBKDR | |
| SCHEMBL18688285 | 0.81 | EGFR (0.62) | METPDGFRAPDGFRBKDRKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2009-02-12 | — | — | US | disclosed |
| EP-1994028-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | AstraZeneca AB (SE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007099335-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | ASTRAZENECA AB (SE) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042910-A1 | QUINOLINE DERIVATIVES FOR TREATING CANCER | RECQL, NQO2, NRAS | MET 3425/4885PDGFRA 2237/4885PDGFRB 2958/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.